Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of the Spectrum of Ophthalmic Changes in Patients With Alagille Syndrome.
da Palma MM, Igelman AD, Ku C, Burr A, You JY, Place EM, Wang NK, Oh JK, Branham KE, Zhang X, Ahn J, Gorin MB, Lam BL, Ronquillo CC, Bernstein PS, Nagiel A, Huckfeldt R, Cabrera MT, Kelly JP, Bakall B, Iannaccone A, Hufnagel RB, Zein WM, Koenekoop RK, Birch DG, Yang P, Fahim AT, Pennesi ME. da Palma MM, et al. Among authors: burr a. Invest Ophthalmol Vis Sci. 2021 Jun 1;62(7):27. doi: 10.1167/iovs.62.7.27. Invest Ophthalmol Vis Sci. 2021. PMID: 34185059 Free PMC article.
A possible ocular biomarker for response to hyperornithinemia in gyrate atrophy: the effect of pyridoxine, lysine, and arginine-restricted diet in a patient with advanced disease.
da Palma MM, Ku C, Igelman AD, Burr A, Shevchenko Sutherland L, Koerner C, Valle D, Pennesi ME, Yang P. da Palma MM, et al. Among authors: burr a. Ophthalmic Genet. 2023 Apr;44(2):191-197. doi: 10.1080/13816810.2022.2098986. Epub 2022 Jul 20. Ophthalmic Genet. 2023. PMID: 35856163
Safety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion study.
Bruce JY, Burr A, Kimple RJ, Adam DP, Yu M, Piaskowski SM, Glazer TA, Hill P, Hartig GK, McCulloch TM, Wieland AM, Trask D, Oliver K, Longcor J, Rogus-Pulia N, Cho SY, Bednarz B, Harari PM. Bruce JY, et al. Among authors: burr a. EBioMedicine. 2024 Dec 12;111:105496. doi: 10.1016/j.ebiom.2024.105496. Online ahead of print. EBioMedicine. 2024. PMID: 39671752 Free PMC article.
Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.
Hammond J, Yunis C, Fountaine RJ, Luscan G, Burr AM, Zhang W, Wisemandle W, Soares H, Baniecki ML, Hendrick VM, Kalfov V, Pypstra R, Rusnak JM. Hammond J, et al. Among authors: burr am. N Engl J Med. 2024 Jul 18;391(3):224-234. doi: 10.1056/NEJMoa2309002. N Engl J Med. 2024. PMID: 39018532 Free PMC article. Clinical Trial.
161 results